Synthesis and antifungal activity of 3-aryl-1,2,4-triazin-6-one derivatives. 2015

W John Owen, and Michael T Sullenberger, and Michael R Loso, and Kevin G Meyer, and Thomas J Slanec
Dow AgroSciences, Indianapolis, IN, USA.

BACKGROUND As a result of resistance development in many plant-pathogenic fungi to agricultural fungicides, there is an ongoing need to discover novel antifungal chemistries to help sustain efficient crop production. A fungicide screening program identified 3-phenyl-1-(2,2,2-trifluoroethyl)-1,2,4-triazin-6(1H)-one (5) as a promising new starting point for further activity optimization. A series of analogs were designed, prepared and evaluated in growth inhibition assays using four plant-pathogenic fungi. RESULTS Thirty nine analogs (compounds 5 to 43) were prepared to explore structure-activity relationships at R1 and R2, and all targeted structures were characterized by (1)H NMR and MS. All compounds were in vitro tested against three ascomycetes [Leptosphaeria nodorum, Magnaporthe grisea and Zymoseptoria tritici (syn. Mycosphaerella graminicola)] and one basidiomycete (Ustilago maydis) pathogen. When R2 was trifluoroethyl, fungicidal activity was enhanced by a single electron-withdrawing substitution, such as Br, Cl and CF3 in the 3-position at R1 (compounds 9, 10 and 12), of which the 3-bromo compound (10) was the most active (EC50 = 0.08, averaged across four pathogens). More subtle activity improvement was found by addition of a second halogen substituent in the 4-position, with the 3-Br-4-F analog (20) being the most active against the commercially important cereal pathogen Z. tritici. Replacement of the R2 haloalkyl group with benzyl, alkyl (e.g. n-butyl, i-butyl, n-pentyl) and, particularly, CH2 -cycloalkyls (e.g. CH2-cyclopropyl, CH2-cyclobutyl) resulted in further activity enhancements against the ascomycete fungi, but was either neutral or detrimental to activity against U. maydis. One of the most active compounds in this series (41) gave control of Z. tritici, with an EC50 of 0.005 ppm, comparable with that of the commercial strobilurin fungicide azoxystrobin (EC50 0.002 ppm). CONCLUSIONS The present work demonstrated that the 3-phenyl-1,2,4-triazin-6-ones are a novel series of compounds with highly compelling levels of antifungal activity against agriculturally relevant plant-pathogenic fungi.

UI MeSH Term Description Entries
D010935 Plant Diseases Diseases of plants. Disease, Plant,Diseases, Plant,Plant Disease
D005659 Fungicides, Industrial Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. Industrial Fungicides
D014227 Triazines Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES. Triazine,Benzotriazines
D014588 Ustilago A genus of basidiomycetous smut fungi comprising the loose smuts. Ustilagos
D020082 Magnaporthe A genus of FUNGI, in the family Magnaporthaceae of uncertain position (incertae sedis). It is best known for its species, M. grisea, which is one of the most popular experimental organisms of all fungal plant pathogens. Its anamorph is PYRICULARIA GRISEA. Magnaporthes

Related Publications

W John Owen, and Michael T Sullenberger, and Michael R Loso, and Kevin G Meyer, and Thomas J Slanec
January 2000, Farmaco (Societa chimica italiana : 1989),
W John Owen, and Michael T Sullenberger, and Michael R Loso, and Kevin G Meyer, and Thomas J Slanec
June 2006, Molecules (Basel, Switzerland),
W John Owen, and Michael T Sullenberger, and Michael R Loso, and Kevin G Meyer, and Thomas J Slanec
January 2004, Acta poloniae pharmaceutica,
W John Owen, and Michael T Sullenberger, and Michael R Loso, and Kevin G Meyer, and Thomas J Slanec
May 2006, Archiv der Pharmazie,
W John Owen, and Michael T Sullenberger, and Michael R Loso, and Kevin G Meyer, and Thomas J Slanec
April 2007, Acta crystallographica. Section C, Crystal structure communications,
W John Owen, and Michael T Sullenberger, and Michael R Loso, and Kevin G Meyer, and Thomas J Slanec
August 1955, Experientia,
W John Owen, and Michael T Sullenberger, and Michael R Loso, and Kevin G Meyer, and Thomas J Slanec
March 2006, Molecules (Basel, Switzerland),
W John Owen, and Michael T Sullenberger, and Michael R Loso, and Kevin G Meyer, and Thomas J Slanec
January 2016, Acta poloniae pharmaceutica,
W John Owen, and Michael T Sullenberger, and Michael R Loso, and Kevin G Meyer, and Thomas J Slanec
September 2009, Molecules (Basel, Switzerland),
W John Owen, and Michael T Sullenberger, and Michael R Loso, and Kevin G Meyer, and Thomas J Slanec
February 2023, European journal of medicinal chemistry,
Copied contents to your clipboard!